How to buy Cyclerion Therapeutics stock (CYCN)

Cyclerion Therapeutics is a biotechnology business based in the US. Cyclerion Therapeutics shares (CYCN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.29 – an increase of 15.64% over the previous week. Cyclerion Therapeutics employs 1 staff and has a trailing 12-month revenue of around $1.3 million.

Our top picks for where to buy Cyclerion Therapeutics stock

Buy Cyclerion Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cyclerion Therapeutics stock price (NASDAQ: CYCN)

Use our graph to track the performance of CYCN stocks over time.

Cyclerion Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$3.29
52-week range	$1.27 - $9.47
50-day moving average more info button	$2.74
200-day moving average more info button	$2.86
Wall St. target price	$4.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.08

Is it a good time to buy Cyclerion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclerion Therapeutics price performance over time

Historical closes compared with the close of $3.2 from 2024-12-23

1 week (2024-12-18)	12.48%
1 month (2024-11-26)	135.29%
3 months (2024-09-25)	16.36%
6 months (2024-06-25)	17.65%

1 year (2023-12-22)	-25.58%
2 years (2022-12-23)	-70.67%
3 years (2021-12-23)	35
5 years (2019-12-24)	49.8

Cyclerion Therapeutics financials

Revenue TTM	$1.3 million
Gross profit TTM	$-29,749,000
Return on assets TTM	-46.55%
Return on equity TTM	-150.25%
Profit margin	0%
Book value	$4.56
Market Capitalization more info button	$7.7 million

TTM: trailing 12 months

Cyclerion Therapeutics share dividends

We're not expecting Cyclerion Therapeutics to pay a dividend over the next 12 months.

Have Cyclerion Therapeutics's shares ever split?

Cyclerion Therapeutics's shares were split on a 1:20 basis on 15 May 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclerion Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cyclerion Therapeutics shares which in turn could have impacted Cyclerion Therapeutics's share price.

Cyclerion Therapeutics share price volatility

Over the last 12 months, Cyclerion Therapeutics's shares have ranged in value from as little as $1.27 up to $9.4699. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclerion Therapeutics's is 1.924. This would suggest that Cyclerion Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cyclerion Therapeutics overview

Cyclerion Therapeutics, Inc. , a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

null
What percentage of Cyclerion Therapeutics is owned by insiders or institutions?
Currently 21.903% of Cyclerion Therapeutics shares are held by insiders and 40.411% by institutions. How many people work for Cyclerion Therapeutics?
Latest data suggests 1 work at Cyclerion Therapeutics. When does the fiscal year end for Cyclerion Therapeutics?
Cyclerion Therapeutics's fiscal year ends in December. Where is Cyclerion Therapeutics based?
Cyclerion Therapeutics's address is: 245 First Street, Riverview II, Cambridge, MA, United States, 02142 What is Cyclerion Therapeutics's ISIN number?
Cyclerion Therapeutics's international securities identification number is: US23255M1053 What is Cyclerion Therapeutics's CUSIP number?
Cyclerion Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23255M105